Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2006

View Archived Issues

D-003 and policosanol compared in patients with hypercholesterolemia

SIR-spheres investigated in cholangiocarcinoma and colorectal cancer metastases

Oxaliplatin tolerability, activity advantageous in colorectal cancer patients

BN-83152, an MC4R antagonist with potential for anorexia/cachexia-related syndromes

Epeius to study Tri-REX Vaccination Protocol in breast cancer

Preclinical update on the insulin-like effect of BFOV

Nisshin Kyorin presents novel mu-opioid antagonists with potential for pruritus

Gestiva NDA accepted for filing

Nobilon and NVI to develop RSV vaccine

LigoCyte's development of mucosal anthrax vaccine supported by DOD grant

MGI licenses ex-North American Dacogen rights to Cilag

Lipsovir begins phase III study for cold sores

King and Wyeth amend Altace copromotion agreement

KPE-02004001 targets C. difficile

New phase II study of 6R-BH4 in poorly controlled hypertension

Locus enters into drug discovery agreement with Ono

Alnylam amends RNAi collaboration agreements with Merck

Ipsen report on new analogues of human MSH for obesity

European Commission approves revision of therapeutic indication for Rebif

Avastin filed in Europe for first-line treatment of advanced breast cancer

Therapeutic agents for arthritis, autoimmune diseases, etc. claimed in recent patent literature

New treatments for cancer covered in recent patent literature

Pfizer launches Zoloft in Japan

Gemzar approved in Japan for biliary cancer

Amlodin OD launched in Japan

Results of phase Ib clinical trial of TACI-Ig reported

Paquinimod from Active Biotech effective in experimental models of arthritis

Takeda presents new preclinical data on TAK-475

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...